Corvus Pharmaceuticals, a preclinical biotech developing checkpoint immunotherapies for solid tumors, announced terms for its IPO on Thursday.
The Washington, DC-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Corvus Pharmaceuticals would command a fully diluted market value of $336 million.
Corvus Pharmaceuticals was founded in 2014. It plans to list on the Nasdaq under the symbol CRVS. Credit Suisse, Cowen & Company and Guggenheim Securities are the joint bookrunners on the deal. It is expected to price during the week of March 21, 2016.
